XORTX Therapeutics Inc. (XRTX)
NASDAQ: XRTX · Real-Time Price · USD
0.8390
-0.0510 (-5.73%)
At close: Nov 20, 2026, 4:00 PM EST
0.8101
-0.0289 (-3.44%)
After-hours: Nov 20, 2026, 7:30 PM EST
XORTX Therapeutics Employees
As of December 31, 2023, XORTX Therapeutics had 3 total employees, including 2 full-time and 1 part-time employees. The number of employees did not change compared to the previous year. That makes XORTX Therapeutics the 43,004th largest employer in the world and 6,927th in the United States.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,157,256
Market Cap
1.88M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2023 | 3 | 0 | - | 2 | 1 |
| Dec 31, 2022 | 3 | 0 | - | 3 | 0 |
| Jan 1, 2022 | 3 | - | - | 3 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Senti Biosciences Holdings | 39 |
| HCW Biologics | 35 |
| Calidi Biotherapeutics | 29 |
| Decoy Therapeutics | 11 |
| Eocene | 6 |
| KALA BIO | 6 |
| Jupiter Neurosciences | 5 |
| 60 Degrees Pharmaceuticals | 3 |
XRTX News
- 6 days ago - XORTX Completes Manufacturing of Clinical Drug Supply - GlobeNewsWire
- 9 days ago - Xortx announces patent allowance by JPO for XRx-101 program - TheFly
- 9 days ago - XORTX Patent Allowed for XRx-101 Program by Japan Patent Office - GlobeNewsWire
- 6 weeks ago - Xortx Therapeutics outlines anticipated clinical trial application for XRx-026 - TheFly
- 6 weeks ago - XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout - GlobeNewsWire
- 2 months ago - Xortx Therapeutics announces planned FDA IND submission for XRx-026 - TheFly
- 2 months ago - XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity - GlobeNewsWire
- 2 months ago - Xortx Therapeutics initiates clinical, commercial manufacturing of Xorlo - TheFly